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Autosomal Recessive  
Congenital Ichthyosis
Judith Fischer1
Recent progress in the genetics of autosomal recessive congenital ichthyosis 
(ARCI) has illustrated the power of genetic strategies for the investigation of 
newly recognized metabolic pathways and for the mechanisms of barrier func-
tion in normal skin. Parallel biochemical studies have elucidated important func-
tional aspects of these findings (Brash et al., 2007), and it is now time to determine 
how the genetic and biochemical features correlate with the clinical phenotypes 
of patients. The story of ARCI provides an instructive example of synergy among 
geneticists, biochemists, and clinicians.
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autosomal recessive congenital 
ichthyosis and its genes
ARCI is a heterogeneous group of dis-
orders of keratinization characterized 
mainly by abnormal skin scaling over 
the whole body. These disorders are 
mostly nonsyndromic and limited to 
skin; a total of 60–70% of patients pres-
ent with severe symptoms, including a 
collodion membrane at birth. The main 
skin phenotypes are lamellar ichthyosis 
and congenital ichthyosiform erythro-
derma, although phenotypic overlap 
in the same patient or in patients of the 
same family can occur. Some patients 
have nonlamellar, nonerythrodermic 
ichthyosis. Since 1995, genetic analyses 
have implicated six genes. Mutations 
in transglutaminase 1 (TGM1), identi-
fied simultaneously by two groups in 
1995 (Huber et al., 1995; Russell et al., 
1995), are the most common cause of 
ARCI. Between 2002 and 2006, five 
other ARCI genes were identified via 
homozygosity mapping in consanguine-
ous families (Jobard et al., 2002; Lefèvre 
et al., 2003, 2004, 2006). These findings 
provided evidence for the existence of 
an epidermis-specific hepoxilin pathway, 
based on the metabolism of arachidonic 
acid. These genes include two lipoxy-
genases (ALOX12B, ALOXE3), an ATP-
binding cassette transporter (ABCA12), a 
potential receptor (ichthyin), and a gene 
coding for a protein of the cytochrome 
P450 family (CYP4F22).
mutational spectrum in arcI
In the study reported in this issue, Eckl 
et al. (2009) present mutation screening 
of ALOX12B and ALOXE3 genes in 250 
ARCI patients. Consanguineous families 
were first tested for homozygous regions 
before sequencing of the corresponding 
genes. Previous analysis of the TGM1 
gene had revealed mutations in 38% of 
patients (data not presented), whereas 
ALOX12B and ALOXE3 mutations were 
found in 17 patients each—6.8% for 
ALOX12B and 6.8% for ALOXE3, includ-
ing 13 patients from a previous publica-
tion (Eckl et al., 2005). Eight of the muta-
tions in ALOX12B and three mutations 
in ALOXE3 were novel. Analysis of the 
literature and the results of this paper 
confirmed the presence of two muta-
tional hotspots in ALOXE3 (p.Arg234X 
and p.Pro630Leu), which were first 
reported by Jobard et al. (2002) and 
Eckl et al. (2005), respectively, whereas 
no recurrent mutations were observed 
in ALOX12B. It is unclear whether 
all 250 patients were sequenced for 
the three genes (TGM1 and the two 
lipoxygenases) that are responsible for 
more than half of the mutations (51.6%). 
Based on Eckl’s estimate that between 
30 and 40% of patients have no muta-
tions in the six known ARCI genes (Eckl 
et al., 2009), mutations in the other 
three genes—ichthyin, CYP4F22, and 
ABCA12—should account for 8–18% of 
the remaining cases.
In our cohort of 520 independent fam-
ilies, however, we were able to identify 
mutations in all but 22% of the patients, 
and we observed differences in the dis-
tribution of mutations in populations of 
different origin. By direct sequencing of 
the six ARCI genes, we found that 32% 
of the patients harbored mutations in 
TGM1, 12% in ALOX12B, and 5% in 
ALOXE3 (49% of the total, similar to the 
51.6% reported by Eckl et al.). Moreover, 
29% of the mutations were situated in 
the three remaining ARCI genes (16% 
in ichthyin, 8% in CYP4F22, and 5% in 
ABCA12) (Figure 1). For a better estima-
tion of the percentages, especially that 
of patients without mutations in the six 
known genes, it will be necessary to 
sequence all ARCI genes in patient col-
lections, including Eckl’s cohort.
causative mutations and polymorphisms
Another issue is the genetic classifi-
cation of patients in whom only one 
mutation has been detected, which Eckl 
et al. (2009) reported in 3 of 34 patients 
(9%). It is well known that larger dele-
tions may play a role in these cases, but 
very few molecular researchers have 
systematically tried to identify such 
large deletions.
Unfortunately, the molecular diag-
nosis remains uncertain in these cases. 
They should not be included in studies of 
genotype–phenotype correlations, even 
when the first mutation is a previously 
detected missense mutation or a muta-
tion leading to a truncated protein.
|Large cohorts are essential to understanding ARCI.
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If a mutation is a missense mutation, 
which leads to a replacement of one 
amino acid in the peptide sequence, it 
is usual to provide the results of screen-
ing in 120 healthy population-matched 
controls. However, there is no guaran-
tee that the mutation is causative when 
it is absent from the general popula-
tion. In the case of autosomal recessive 
disorders, there are four to five times 
more healthy carriers than affected 
individuals in the general population, 
so the detection of carriers in such pop-
ulation-matched controls is insufficient 
proof to classify a sequence variation 
as a noncausative polymorphism. The 
strategy used by Eckl et al. (2009) to test 
for enzymatic activity was especially 
helpful in determining whether the mis-
sense mutations in the ALOXE3 and 
ALOX12B genes were causative.
The authors have provided a didactic 
example of the difficulties of molecu-
lar diagnosis with patient ISA, from the 
Indian subcontinent, who was previ-
ously reported to harbor a homozygous 
p.Leu237Met mutation in ALOXE3 but 
in whom this mutation was shown to 
have normal enzymatic activity using a 
construct created by site-directed muta-
genesis (Eckl et al., 2005). This patient, 
in whom no consanguinity was initially 
known, was described as presenting 
with a remarkably severe phenotype, 
including erythroderma; large thick, 
dark scales over his entire body; and 
facial involvement, symptoms that are 
more characteristic of TGM1 mutations, 
as noted by the authors. In the cur-
rent article, the mystery about patient 
ISA continues: a second homozygous 
mutation is now reported (p.Arg145His) 
in exon 3 of ALOXE3; it was also 
described as enzymatically active but 
was later found to correspond function-
ally to a splice site mutation leading to 
a skipped exon (p.Arg119GlyfsX12). 
Phenotypic information is absent from 
the current article.
Genotype–phenotype correlation
Because the ARCI group of disorders is 
characterized by both genetic and clin-
ical heterogeneity, the genetic forms 
cannot be clearly distinguished based 
on the phenotype. Our attempts to 
correlate the skin phenotype of patients 
from 520 families with a specific 
genotype were successful (manuscript 
in preparation) in only about one-
third of the cases. However, we have 
observed that clinical criteria such as 
hyper linearity and general or partial 
hyperkeratosis of the palms and soles 
are often more genotype specific than 
are the details about skin pheno type. 
Therefore, it is to be expected that a 
clear palmoplantar description would 
provide a more precise “prediction 
score” for the genotype–phenotype 
correlation.
As reported in this issue, Eckl et 
al. describe a significant phenotypic 
variation in ARCI resulting from 
ALOX12B and ALOXE3 mutations, based 
on the presence or absence of keratoder-
ma, respectively. Other clinical features, 
such as alopecia and hypohydrosis, did 
not exhibit significant differences, but 
it is possible that these differences are 
more striking in patient groups in which 
the causative genes do not exhibit a 
close functional relationship, as is the 
case with ALOXE3 and ALOX12B. It is 
also possible that examination of more 
than 34 patients will be necessary to 
detect statistical differences.
The immense importance of large col-
lections of patients and families for the 
complete study of these heterogeneous 
disorders has become evident. These 
collections allow the identification of 
genes that are causative in only a very 
small group of patients, and they can 
help to identify genotype–phenotype 
correlations.
A complete list or database of sequence 
variations found in ARCI patients, 
including information about causative 
mutations and noncausative poly morph-
isms and corresponding clinical data, 
would be useful for diagnosis and for 
future projects, including clinical trials.
In several cases, sequence variations 
reported as causative mutations (cf. 
p.P127S in ALOX12B; Eckl et al., 2005) 
have turned out to be neutral polymor-
phisms (Lesueur et al., 2007). Clear and 
precise clinical information such as that 
reported by Eckl et al. in this issue (see 
the supplementary information for that 
article) will be very useful in this type 
of study.
A more precise clinical classifica-
tion that takes into account key ele-
ments of ARCI (such as palmoplantar 
features) would certainly be useful for 
correlations with genotypes. However, 
most ARCI patients have no access to 
mutation screening because of the high 
screening costs and the large number 
of genes that must be analyzed in the 
absence of clear phenotypic correlation 
with specific gene mutations. Therefore, 
the development of a diagnostic chip 
that could provide less expensive and 
more complete diagnosis should be 
a priority for both patients and clini-
cians. The future will show whether the 
lessons learned in the genetic, biochem-
ical, and clinical analyses of ARCI will 
finally lead to a revolution in treatment.
Figure 1. Distribution of mutations in a cohort of 520 ARCI families. The results of direct sequencing 
of 520 patients from 520 independent families; 32% of the patients present mutations in TGM1, 16% in 
ichthyin, 12% in ALOX12B, 8% in CYP4F22, and 5% each in ALOXE3 and ABCA12 (only exons 28–32 were 
sequenced in ABCA12 for the majority of patients). In 22% of the patients, no mutations could be detected.
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shedding Light on Proteolytic 
Cleavage of CD44:  
The Responsible sheddase and 
Functional significance of shedding
Ivan Stamenkovic1 and Qin Yu2
CD44 is the major cell-surface receptor for hyaluronan, which is implicated 
in cell–cell and cell–matrix adhesion, cell migration, and signaling. studies 
have shown that CD44-dependent migration requires CD44 to be shed from 
the cell surface and that matrix metalloproteinase–mediated cleavage may 
provide an underlying mechanism. However, the full spectrum of proteases 
that may participate in CD44 shedding has yet to be defined. In this issue, 
Anderegg et al. demonstrate that ADAM10, but not ADAM17 or MMP14, 
mediates constitutive shedding of CD44 in human melanoma cells and that 
knockdown of ADAM10 blocks the antiproliferative activity of the soluble 
proteolytic cleavage product of CD44.
Journal of Investigative Dermatology (2009) 129, 1321–1324. doi:10.1038/jid.2009.13
roles of cD44 and aDam10 
in melanoma progression
Studies have suggested an important 
role for CD44 in melanoma growth and 
progression. Thus, increased expression 
of CD44 and CD44–hyaluronan (HA) 
interaction correlate, respectively, with 
melanoma progression and metastatic 
proclivity of melanoma cells (De Wit et 
al., 1996). CD44 mediates HA-induced 
melanoma cell proliferation (Ahrens et 
al., 2001a), and CD44–HA interaction is 
required for melanoma development in 
mouse models (Bartolazzi et al., 1994). 
Functional blocking anti-CD44 antibody 
inhibits growth and metastasis of human 
melanoma cells (Guo et al., 1994), and 
soluble CD44 inhibits melanoma tumor 
growth by blocking HA binding to cell-
surface CD44 (Ahrens et al., 2001b). 
In addition, hepatocyte growth fac-
tor engagement of its receptor, c-Met, 
upregulates expression of CD44v6 in 
murine melanoma cells (Recio and 
Merlino, 2003), and HA-mediated inter-
action between CD44 and epidermal 
growth factor receptor promotes mela-
noma cell motility by activating protein 
kinase C signaling (Kim et al., 2008).
ADAM (a disintegrin and metallo-
proteinase) is a family of cell-surface 
proteases that are related to matrix 
metal loproteinases (MMPs) and contain 
several defined functional domains, 
including metalloproteinase, disinteg-
rin, cysteine-rich, and transmembrane 
domains, as well as a cytoplasmic tail. 
ADAMs serve as the major class of shed-
dases for many important cell-surface 
receptors, and they play an essential 
role in regulating interactions between 
tumor cells and their microenvironment 
and in initiating the activation of key 
signaling pathways. Expression levels 
of many ADAM family members are 
elevated in human cancers, and stud-
ies have suggested important roles for 
ADAMs in cancer growth and pro-
gression (reviewed by Mochizuki 
and Okada, 2007). Currently, little is 
known about the role of ADAM10 and 
the other ADAM family members in 
